
|Videos|July 11, 2017
Phase III Findings for Lenvatinib in HCC
Author(s)Ann-Lii Cheng, MD
Ann-Lii Cheng, MD, discusses a phase III trial of lenvatinib vs sorafenib in the first-line treatment of patients with unresectable hepatocellular carcinoma.
Advertisement
Advertisement
Related Content
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Multimodal AI Outperforms Oncotype DX in Predicting Late Breast Cancer Recurrence
2
T-DXd Benefit Consistent Across Subgroups in High-Risk HER2+ Breast Cancer
3
Sacituzumab Govitecan Improves QOL in Untreated Advanced TNBC
4
FDA Grants Priority Review to Nivolumab-AVD in Classical Hodgkin Lymphoma
5









































